Opinion|Videos|June 11, 2025
An Overview on The Root Causes of Duchenne Muscular Dystrophy
Author(s)Jeffrey Chamberlain, PhD
A panelist discusses how DMD is caused genetically through mutations in the dystrophin gene, with approximately one-third of cases arising from spontaneous new mutations rather than inherited from carrier parents.
Advertisement
Clinical Brief: Genetic Foundations and Diagnostic Approaches in DMD
Main Discussion Topics
- DMD results from mutations in the dystrophin gene, the largest known human gene
- Approximately one-third of cases arise from spontaneous new mutations
- Two primary mutation categories: those preventing dystrophin production (DMD) and those allowing partial function (BMD)
- Diagnostic approaches include genetic sequencing and muscle biopsy for protein assessment
Key Points for Physicians
- Modern genetic sequencing has largely replaced PCR methods for mutation identification
- Genetic testing alone cannot always reliably predict disease progression
- Muscle biopsy can provide valuable information about dystrophin quantity and quality
- Genotype-phenotype correlation is imperfect; some patients progress differently than predicted
Notable Insights
The expert emphasizes the unpredictable relationship between specific mutations and clinical presentation. Some patients expected to develop milder Becker phenotype may present with more severe Duchenne features, while others with apparent DMD mutations may have unexpectedly milder progression.
Clinical Significance
Comprehensive diagnostic evaluation combining genetic mutation identification with functional protein assessment provides the most accurate basis for prognosis and therapeutic planning in dystrophinopathies.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
- Setting Realistic Expectations for Antiamyloid Therapeutics
September 11th 2025
- Monitoring and Managing ARIA in Antiamyloid Treatments
September 10th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
NeurologyLive® Brain Games: September 14, 2025
5